Methylene blue adjuvant therapy of schizophrenia (1997)

Peer-Reviewed Study · Authors as listed in the Clinical Neuropharmacology record · August 1997

Authors as listed in the Clinical Neuropharmacology record, 1997-08: Preliminary open-label study adding oral methylene blue to conventional antipsychotics in eight poorly responsive schizophrenia patients over four weeks, rating symptoms weekly.

Participants in the current study were eight patients with schizophrenia who had incomplete responses to conventional antipsychotics

abstract

Authors as listed in the Clinical Neuropharmacology record, 1997-08: Preliminary open-label study adding oral methylene blue to conventional antipsychotics in eight poorly responsive schizophrenia patients over four weeks, rating symptoms weekly. Study type: open-label, uncontrolled pilot (1 week off, 2 weeks on, 1 week off). N=8. Country: not stated in abstract. Dose/route/schedule: oral methylene blue as adjuvant; dose not stated in abstract. Comparator: none (within-patient on/off design). Funder/conflicts: not stated in abstract. Very small and uncontrolled – the authors themselves call it preliminary. Study type: uncontrolled series.